Report
Life sciences and healthcare insights
Welcome to Life sciences and healthcare insights, where we explore the most important commercial, legal, and regulatory issues facing life sciences and healthcare companies around the world.
As innovation accelerates and geopolitical, technological, and policy pressures intensify, life sciences and healthcare companies are traversing an increasingly complex risk and opportunity landscape. Against this backdrop our global team examines the following topics.
Why life sciences and healthcare companies are attracting heightened attention from activist funds and what boards can do in response.
With AI-driven partnerships, acquisitions, and collaborations gathering pace, how data quality, consent, ownership, and regulatory compliance are increasingly central to deal value and risk allocation.
The deal structures Chinese innovators are using to expand internationally, and the regulatory, IP, and data‑transfer considerations shaping these transactions.
The proposed revisions to the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), and how Europe’s expanding environmental and sustainability agenda is reshaping the regulatory and compliance landscape.
Two years on from its launch, the UPC’s impact on European patent litigation and what its growing body of case law means for life sciences companies.
Download this report
Dive into the report
Here you will find links to each of the articles in our report. Together they highlight the continued evolution of the life sciences and healthcare industry globally.
